Consolidated Statement Of Profit Or Loss

Nxera Pharma Co., Ltd. - Filing #7272710

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Consolidated statement of profit or loss
Statement of profit or loss
Revenue
28,835,000,000 JPY
12,766,000,000 JPY
Cost of sales
7,616,000,000 JPY
3,102,000,000 JPY
Gross profit
21,219,000,000 JPY
9,664,000,000 JPY
Selling, general and administrative expenses
16,015,000,000 JPY
9,965,000,000 JPY
Other income
1,289,000,000 JPY
944,000,000 JPY
Other expenses
100,000,000 JPY
94,000,000 JPY
Operating profit (loss)
-5,423,000,000 JPY
-9,526,000,000 JPY
Finance income
1,544,000,000 JPY
1,341,000,000 JPY
Finance costs
783,000,000 JPY
2,495,000,000 JPY
Profit (loss) before tax
-4,662,000,000 JPY
-10,680,000,000 JPY
Income tax expense
176,000,000 JPY
-3,487,000,000 JPY
Profit (loss)
JPY
-4,838,000,000 JPY
-4,838,000,000 JPY
JPY
-4,838,000,000 JPY
JPY
JPY
-7,193,000,000 JPY
-7,193,000,000 JPY
JPY
JPY
-7,193,000,000 JPY
JPY
JPY
Profit (loss) attributable to
Owners of parent
-4,838,000,000 JPY
-7,193,000,000 JPY
Earnings (loss) per share
Basic earnings (loss) per share
-53.92
-87.18
Diluted earnings (loss) per share
-53.92
-87.18

Talk to a Data Expert

Have a question? We'll get back to you promptly.